Telix Pharmaceuticals turned profitable in FY25 with revenue up 56% to US$803.8M. The radiopharma leader now guides FY26 to US$950-970M, putting it in a different category for fund managers rotating toward healthcare.
Alpha Score of 58 reflects moderate overall profile with poor momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Telix Pharmaceuticals crossed into sustained profitability in FY25, a milestone that separates it from most clinical-stage biotechs and puts the stock in a different category for fund managers rotating toward healthcare.
The radiopharmaceuticals developer reported revenue of US$803.8 million, up 56% from the prior year, driven by its two commercial products Illuccix and Gozellix. Adjusted EBITDA turned positive, and management guided FY26 revenue to US$950-970 million, implying another 18-20% of top-line growth at the midpoint.
The numbers matter because they answer the question that has hung over Telix since its early days: can a radiopharma company actually build a recurring revenue business, or is it just a pipeline story with periodic binary events? The FY25 result says the former. Illuccix, used for prostate cancer imaging, has become the standard of care in a growing number of U.S. hospitals, and Gozellix is expanding the addressable market into kidney cancer.
AlphaScala's proprietary scoring system rates TLX at 58 out of 100, a Moderate label that reflects the transition from pre-revenue risk to commercial-stage execution. The score sits in the middle of the pack for ASX healthcare names, which makes sense for a company that has proven its product-market fit but still faces the usual scaling risks: manufacturing capacity, reimbursement expansion, and competition from larger players entering the radiopharma space.
The broader market context helps Telix's case. The ASX small-cap rotation that played out this week favored healthcare and technology over financials and materials, with the S&P/ASX 200 closing Friday at 8,804.0 after a 1.98% surge. Bond yields near three-month lows and fading rate-hike expectations have pushed investors toward businesses with predictable revenue streams and global exposure. Telix fits that description better than most ASX healthcare names because its revenue is dollar-denominated and its customer base is concentrated in the U.S., the world's largest healthcare market.
The risk is valuation. Telix trades at a multiple that assumes continued high growth, and any miss on the FY26 guidance would reset expectations hard. The company also faces the usual biotech overhang: pipeline setbacks in its therapeutic programs could overshadow the diagnostics business even if commercial revenue keeps growing.
For now, the FY25 result gives the bull case a foundation it lacked when Telix was still burning cash. The question for the next 12 months is whether the revenue trajectory can sustain the multiple, or whether the market will demand more evidence of durability before assigning a premium.
Follow the TLX stock page for ongoing coverage.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.